Oxytocin Hormone – Widely Used as an Autism Treatment – Shows No Benefit

Autistic Boy Autism Concept

A large national study found no evidence that oxytocin helps children with autism gain social skills.

Multicenter study finds that oxytocin was safe, but ineffective at boosting social skills among children with autism.

Oxytocin, a naturally occurring hormone that acts as a chemical messenger in the brain, showed no evidence of helping children with autism gain social skills, according to a large national study appearing today (October 13, 2021) in the New England Journal of Medicine.

While disappointing for those holding hope that oxytocin could benefit children with autism, the long-awaited finding provides clarity for a drug that has shown mixed outcomes in smaller, less robust studies.

“There was a great deal of hope this drug would be effective,” said the study’s principal investigator and lead author, Linmarie Sikich, M.D., associate consulting professor in the Department of Psychiatry & Behavioral Sciences at Duke University School of Medicine. “All of us on the study team were hugely disappointed, but oxytocin does not appear to change social function of people with autism.”

Oxytocin is typically used to induce labor, but because of its activity in the brain, it has been investigated as a treatment for autism. Evidence has been conflicting, with several smaller studies suggesting it improved social and cognitive function among some children with autism, while other studies showed no benefit.

Sikich and colleagues, including senior author Jeremy Veenstra-VanderWeele, M.D., of New York State Psychiatric Institute and Columbia University, designed the multi-site trial to provide the best evidence yet about whether oxytocin was a safe and effective treatment for children with Autism Spectrum Disorder.

The research team enrolled 290 children ages 3-17, stratified by age and the severity of their autism symptoms. The children were randomized in similar, equal-sized groups to receive oxytocin or a placebo via a daily nasal spray over 24 weeks.

The study aimed to see if the regimen of oxytocin would have a measurable impact on the children’s social abilities based on screenings and assessments at the start of the trial, midway through, and at the end. Both researchers and the children’s parents provided assessments using standard analytic tools for autism.

While the oxytocin was well tolerated and had few side effects, it showed no significant benefit among the group of children who received it compared to those who received the placebo.

“Thousands of children with autism spectrum disorder were prescribed intranasal oxytocin before it was adequately tested,” Veenstra-VanderWeele said. “Thankfully, our data show that it is safe. Unfortunately, it is no better than placebo when used daily for months. These results indicate that clinicians and families should insist that there is strong evidence for the safety and benefit of new treatments before they are provided to patients in the clinic.”

Sikich said no further study is likely of oxytocin, given the negative findings: “Our consensus as investigators is that there is no evidence in this large study that is strong enough to justify more investigation of oxytocin as a treatment for autism spectrum disorders.”

Reference: “Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder” by Linmarie Sikich, M.D., Alexander Kolevzon, M.D., Bryan H. King, M.D., Christopher J. McDougle, M.D., Kevin B. Sanders, M.D., Soo-Jeong Kim, M.D., Marina Spanos, Ph.D., Tara Chandrasekhar, M.D., M.D. Pilar Trelles, M.D., Carol M. Rockhill, M.D., Michelle L. Palumbo, M.D., Allyson Witters Cundiff, M.D., Alicia Montgomery, M.B., B.S., Paige Siper, Ph.D., Mendy Minjarez, Ph.D., Lisa A. Nowinski, Ph.D., Sarah Marler, M.A., Lauren C. Shuffrey, Ph.D., Cheryl Alderman, B.S., Jordana Weissman, B.A., Brooke Zappone, B.S., Jennifer E. Mullett, R.N., Hope Crosson, B.S.W., Natalie Hong, M.S., Stephen K. Siecinski, B.S., Stephanie N. Giamberardino, Sc.M., Sheng Luo, Ph.D., Lilin She, Ph.D., Manjushri Bhapkar, M.S., Russell Dean, M.S., Abby Scheer, M.S.I.S., Jacqueline L. Johnson, Dr.P.H., Simon G. Gregory, Ph.D. and Jeremy Veenstra-VanderWeele, M.D., 14 October 2021, New England Journal of Medicine.
DOI: 10.1056/NEJMoa2103583

In addition to Sikich and Veenstra-VanderWeele, study authors include Alexander Kolevzon,  Bryan H. King, Christopher J. McDougle, Kevin B. Sanders, Soo-Jeong Kim, Marina Spanos, Tara Chandrasekhar, Pilar Trelles, Carol M. Rockhill, Michelle L. Palumbo, Allyson Witters Cundiff, Alicia Montgomery, Paige Siper, Mendy Minjarez, Lisa A. Nowinski, Sarah Marler, Lauren C. Shuffrey, Cheryl Alderman, Jordana Weissman, Brooke Zappone, Jennifer E. Mullett, Hope Crosson, Natalie Hong, Stephen K. Siecinski, Stephanie N. Giamberardino, Sheng Luo, Lilin She, Manjushri Bhapkar, Russell Dean and Abby Scheer.

The study received funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (U01HD073984) and the National Center for Advancing Translational Sciences (UL1TR002489).

1 Comment on "Oxytocin Hormone – Widely Used as an Autism Treatment – Shows No Benefit"

  1. Stuart Malseed | August 16, 2022 at 6:06 pm | Reply

    Any known link between autism and epidural needle at birth?

Leave a comment

Email address is optional. If provided, your email will not be published or shared.